For the quarter ending 2026-03-31, SYRE has $763,953K in assets. $93,142K in debts. $97,185K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 97,185 | 85,721 | 64,897 | 81,659 |
| Marketable securities | 644,282 | 670,812 | 421,301 | 444,921 |
| Prepaid expenses and other current assets | 22,486 | 21,248 | 18,406 | 12,252 |
| Total current assets | 763,953 | 777,781 | 504,604 | 538,832 |
| Other non-current assets | - | 0 | 0 | 0 |
| Total assets | 763,953 | 777,781 | 504,604 | 538,832 |
| Accounts payable-Nonrelated Party | 5,692 | 8,904 | 7,457 | 3,712 |
| Cvr liability | 50,260 | 22,820 | 11,020 | 59,900 |
| Accrued and other current liabilities | 29,160 | 26,947 | 23,827 | 19,416 |
| Related party accounts payable-Related Party | 50 | 14 | 3,970 | 31 |
| Total current liabilities | 85,162 | 58,685 | 46,274 | 83,059 |
| Non-current cvr liability | 6,690 | 3,860 | 3,230 | 0 |
| Other non-current liabilities | 1,290 | - | - | - |
| Total liabilities | 93,142 | 62,545 | 49,504 | 83,059 |
| Preferred stock-Series ANon Voting Convertible Preferred Stock | 146,425 | 146,425 | 146,425 | 146,425 |
| Preferred stock-Series BNon Voting Convertible Preferred Stock | 9,395 | 9,395 | 9,395 | 9,395 |
| Preferred stock-Preferred Stock Excluding Series AAnd BNon Voting Convertible Preferred Stock | 0 | 0 | 0 | 0 |
| Common stock, 0.0001 par value 400,000,000 shares authorized as of march31, 2026 and december31, 2025 78,839,858 shares and 78,189,811 shares issued and outstanding as of march31, 2026 and december31, 2025, respectively | 15 | 15 | 13 | 13 |
| Additional paid-in capital | 1,712,383 | 1,686,167 | 1,363,581 | 1,353,408 |
| Accumulated other comprehensive (loss) income | -767 | 869 | 791 | 454 |
| Accumulated deficit | -1,196,640 | -1,127,635 | -1,065,105 | -1,053,922 |
| Total stockholders equity | 670,811 | 715,236 | 455,100 | 455,773 |
| Total liabilities, convertible preferred stock and stockholders equity | 763,953 | 777,781 | 504,604 | 538,832 |
Spyre Therapeutics, Inc. (SYRE)
Spyre Therapeutics, Inc. (SYRE)